Decreased expression of TRPV1 in renal cell carcinoma: association with tumor Fuhrman grades and histopathological subtypes

Abstract

PurposeThe aim of this study was to investigate whether the expression of the ligand-gated Ca2+ channel transient receptor potential vanilloid type-1 (TRPV1) in primary human renal cell carcinoma (RCC) is associated with clinicopathological features.Patients and methodsFresh and frozen primary tumor and normal peritumoral kidney tissues from 127 patients diagnosed with RCC were analyzed for TRPV1 expression by quantitative reverse transcription polymerase chain reaction (RT-PCR), Western blotting and immunohistochemistry.ResultsQuantitative RT-PCR revealed that TRPV1 was decreased 3.20-fold in RCC tissue vs normal peritumoral kidney tissue (p=0.012). Significantly different TRPV1 mRNA expression was detected in RCC tissues of different Fuhrman grades and histopathological subtypes (F=4.282, p=0.015 and F=5.205, p=0.014, respectively). Decreased TRPV1 expression was correlated with RCC histopathological subtype (R=-0.554, p=0.003) and Fuhrman grade (R=−0.525, p=0.006). Western blot analysis of TRPV1 protein expression showed similar results. Immunohistochemical analysis showed strong expression of TRPV1 in kidney tubules but demonstrated weak or no immunostaining in RCC tissues.ConclusionTRPV1 expression was decreased in RCC, which was significantly associated with tumor Fuhrman grades and histopathological subtypes. It seems to suggest that TRPV1 expression may be a valuable tool to predict the extent of RCC progression.

TRPV1 acts as a Tumor Suppressor and is associated with Immune Cell Infiltration in Clear Cell Renal Cell Carcinoma: evidence from integrated analysis

“…However, the exact role of TRPV1 in immune systems is not wholly determined. In ccRCC, TRPV1 was demonstrated a decreased expression but negatively correlated with tumor grades and subtypes in study by Wu et al [21], and its detailed effects on the origin, progression and TME of ccRCC are currently unsolved.…”

<p>miR-106b promotes proliferation and invasion by targeting Capicua through MAPK signaling in renal carcinoma cancer</p>

“…The approximate tumor volume was calculated using the equation V = (length × width × width)/2. Once palpable tumors volumes reached 30-40 mm 3 , the animals were randomized into three groups. Mice were injected vein tail injection once weekly with anti-miR-106b virus (anti-miR-106b), negative vector virus (NC).…”

“…1 Approximately one-third patients have metastasis when diagnosed as RCC, 2 so it is urgent to find a new molecular biomarker for RCC diagnosis at the early stage. As reported, genetic biomarkers for RCC have been widely investigated including molecules [3][4][5] and microRNAs (miRNAs). 6,7 miRNAs is a class of endogenous small non-coding RNAs, the length of which is approximately 19-22 nucleotides.…”

Transient Receptor Potential (TRP) Channels in Head-and-Neck Squamous Cell Carcinomas: Diagnostic, Prognostic, and Therapeutic Potentials

“…Unfortunately, changes in TRP expressions appear to be cancer-specific. For instance, TRPV1 expression is increased in HNSCC [ 3 ] and prostate cancer [ 132 ] but is markedly reduced or absent in renal cell carcinoma [ 102 ] or urothelial carcinoma [ 116 ]. Moreover, TRPV2 overexpression heralds poor prognosis in esophageal SCC [ 105 ], but identifies a subgroup of triple-negative breast cancer patients with favorable prognosis [ 114 ].…”

“…Taken together, these findings suggest that increased TRPV1-like immunoreactivity may aid pathologists in distinguishing reactive and malignant oral squamous mucosal lesions. Interestingly, the reverse seems to be true for kidney cancer where TRPV1 is strongly expressed in normal renal tubules with much reduced (or absent) expression in renal cell carcinoma [ 102 ]. Moreover, TRPV1 is a potential negative prognostic marker in breast cancer where TRPV1 expression in the endoplasmic reticulum and Golgi apparatus (and/or the surrounding of these structures) heralds poor prognosis [ 103 ].…”